17-AAG (Tanespimycin)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

17-AAG (Tanespimycin) Chemical Structure

Molecular Weight(MW): 585.69

17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. 17-AAG (Tanespimycin) purchased from Selleck.

    Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. 17-AAG (Tanespimycin) purchased from Selleck.

  • Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. 17-AAG (Tanespimycin) purchased from Selleck.

    UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. 17-AAG (Tanespimycin) purchased from Selleck.

  • Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. 17-AAG (Tanespimycin) purchased from Selleck.

    SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. 17-AAG (Tanespimycin) purchased from Selleck.

  • Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. 17-AAG (Tanespimycin) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description 17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NXnWclBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\zPGlEPTB;MD6wNFA{ODNizszN NFS1NIJUSU6JRWK=
IST-MEL1 M1:4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\PVFNKSzVyPUCuNFAxPDB5IN88US=> M{Pld3NCVkeHUh?=
NCI-SNU-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PEOGlEPTB;MD6wNFIxPyEQvF2= M2L4PXNCVkeHUh?=
FADU MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfqd4VKSzVyPUCuNFAzODlizszN MWHTRW5ITVJ?
C32 NHvjbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvNTWM2OD1yLkCwN|A1KM7:TR?= MWTTRW5ITVJ?
D-566MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnoS|RLUUN3ME2wMlAxOzlizszN NUHkbYpDW0GQR1XS
LXF-289 NHn6OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1yLkCwOFE6KM7:TR?= M{fvSXNCVkeHUh?=
HGC-27 M1Ho[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\RWXc6UUN3ME2wMlAxPTFizszN MkDkV2FPT0WU
RPMI-7951 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMEC3NVch|ryP NF;xZWZUSU6JRWK=
HSC-3 NWr4cXBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXFZ4ZRUUN3ME2wMlAxQTJ7IN88US=> MXrTRW5ITVJ?
MIA-PaCa-2 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[xTWM2OD1yLkCxNFA6KM7:TR?= MX\TRW5ITVJ?
KS-1 Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTVTWM2OD1yLkCxN|U2KM7:TR?= NVjOU4d5W0GQR1XS
CAL-51 M2HKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEG0NFUh|ryP M{jQeXNCVkeHUh?=
MDA-MB-361 M{jKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7rU4FKSzVyPUCuNFE1QTVizszN MoT3V2FPT0WU
TI-73 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrSNHBKSzVyPUCuNFE4QTZizszN NVHyT2t4W0GQR1XS
AGS M4rpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLKTWM2OD1yLkCxPVM5KM7:TR?= NHThPWlUSU6JRWK=
NCI-H460 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEG5O|Qh|ryP NXTU[4REW0GQR1XS
A204 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WyT2lEPTB;MD6wNlI1QSEQvF2= NVHSZY9{W0GQR1XS
CHL-1 NWfXc2FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LmOmlEPTB;MD6wNlI2OSEQvF2= NVXmOXF[W0GQR1XS
DU-4475 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS0TWM2OD1yLkCyNlYyKM7:TR?= NHzjcVdUSU6JRWK=
CGTH-W-1 M{XaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\4O2lEPTB;MD6wNlM1QSEQvF2= MmnGV2FPT0WU
HCC2218 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7W[G1uUUN3ME2wMlAzPDl2IN88US=> M2HISHNCVkeHUh?=
A2780 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3rTWM2OD1yLkCyOVMyKM7:TR?= M2nJbXNCVkeHUh?=
NCI-H720 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OzeWlEPTB;MD6wNlU1PiEQvF2= NHH2TGxUSU6JRWK=
NCI-N87 M4ntb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEK1PVMh|ryP NFG0NpFUSU6JRWK=
CHP-212 M3fjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvseGRKSzVyPUCuNFI3OjhizszN M4PkN3NCVkeHUh?=
NCI-H23 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPjXZZKSzVyPUCuNFI3PjVizszN M1vlbnNCVkeHUh?=
D-263MG M1PiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H5SWlEPTB;MD6wNlc5PiEQvF2= M3;hdHNCVkeHUh?=
ME-180 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33qRWlEPTB;MD6wNlg6OSEQvF2= MmCzV2FPT0WU
SW982 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK0TWM2OD1yLkCyPVk6KM7:TR?= MlS5V2FPT0WU
OE19 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXxTWM2OD1yLkCzNFc4KM7:TR?= MX7TRW5ITVJ?
SK-LU-1 NXPUUVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nxfWlEPTB;MD6wN|A5OiEQvF2= MWfTRW5ITVJ?
H4 NIT6cJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPJS|RzUUN3ME2wMlA{ODlizszN NVrCU2RsW0GQR1XS
HT-144 NUfTdoVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEOwPVMh|ryP NYnDW|U2W0GQR1XS
SK-UT-1 NYniOoxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH5TWM2OD1yLkCzNVc5KM7:TR?= MYLTRW5ITVJ?
D-336MG NWL2VlNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjh[JJKSzVyPUCuNFM{ODlizszN MV7TRW5ITVJ?
MDA-MB-175-VII MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zrfWlEPTB;MD6wN|M2PCEQvF2= Mo\2V2FPT0WU
GAMG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXld4o3UUN3ME2wMlA{PDN3IN88US=> NEnaNYRUSU6JRWK=
CP50-MEL-B MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzJ[m1KSzVyPUCuNFM1PSEQvF2= MknzV2FPT0WU
OVCAR-5 NXiwfmtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f0R2lEPTB;MD6wN|Q5KM7:TR?= NYrTUpBoW0GQR1XS
SK-MES-1 NFHqTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPOTWM2OD1yLkCzOlA3KM7:TR?= MULTRW5ITVJ?
VM-CUB-1 NHHOR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEO2OVch|ryP NV:3U2UzW0GQR1XS
WM-115 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTYTlRoUUN3ME2wMlA{PzZ{IN88US=> MoLJV2FPT0WU
DSH1 NWHBcVVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTtTYs2UUN3ME2wMlA{QDB5IN88US=> MUTTRW5ITVJ?
Becker M3zDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEO4PFUh|ryP NXzMNJhyW0GQR1XS
SW962 NWiwb4lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEO5OFUh|ryP NWnY[plLW0GQR1XS
TYK-nu NUHwN45IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEO5PFUh|ryP NHXo[4hUSU6JRWK=
HO-1-N-1 NEnMS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMESwNlEh|ryP MYHTRW5ITVJ?
T98G Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLseoVKSzVyPUCuNFQyODNizszN M1q1THNCVkeHUh?=
ACN M1rwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD1yLkC0NVYzKM7:TR?= NFPORo1USU6JRWK=
SW780 M1\CWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPN[lhKSzVyPUCuNFQzODNizszN NX2xTooxW0GQR1XS
Detroit562 M3K5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq1PYRKSzVyPUCuNFQzOzlizszN M{m0cXNCVkeHUh?=
BB49-HNC NXHwbIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTUXIxKSzVyPUCuNFQzPDNizszN NXSwRplPW0GQR1XS
HN MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nwRmlEPTB;MD6wOFI4OiEQvF2= NXy2VJpjW0GQR1XS
H9 M3nwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMESzO|Eh|ryP NW\INGNTW0GQR1XS
VA-ES-BJ MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[xTWM2OD1yLkC0OFQ4KM7:TR?= NF;Ze|dUSU6JRWK=
MEL-JUSO MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jwS2lEPTB;MD6wOFQ4PSEQvF2= NGXtbnZUSU6JRWK=
BT-474 NGLrTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLlTWM2OD1yLkC0OUDPxE1? MkfjV2FPT0WU
CaR-1 NVjJU2JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;OSmlEPTB;MD6wOFU1QSEQvF2= NX\uSYxTW0GQR1XS
PSN1 M2nGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HISmlEPTB;MD6wOFYxOyEQvF2= NYXnZoxTW0GQR1XS
KYSE-510 M4q0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nEOGlEPTB;MD6wOFY1QSEQvF2= M1TMOnNCVkeHUh?=
KP-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4XWlEPTB;MD6wOFc2OyEQvF2= M33rNnNCVkeHUh?=
KYSE-410 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPUTWM2OD1yLkC0O|czKM7:TR?= MlrYV2FPT0WU
G-402 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\QXJNKSzVyPUCuNFQ4QDlizszN NIT5N41USU6JRWK=
DOK M3\JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMES5NFIh|ryP MXnTRW5ITVJ?
COR-L88 M{\iOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PwZWlEPTB;MD6wOFkyOiEQvF2= NV7jSHFtW0GQR1XS
SKG-IIIa MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDMZpBKSzVyPUCuNFQ6QDZizszN M2\6cXNCVkeHUh?=
AN3-CA MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrsVZJKSzVyPUCuNFUh|ryP MnfWV2FPT0WU
SW48 NHHORZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfPbZhKSzVyPUCuNFUxOzlizszN MX7TRW5ITVJ?
YKG-1 NVnPPZNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonoTWM2OD1yLkC1NFcyKM7:TR?= NUjRT|FbW0GQR1XS
KYSE-150 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX3TWM2OD1yLkC1NlM2KM7:TR?= NYfJUIl7W0GQR1XS
HuO-3N1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu3b25KSzVyPUCuNFUzOzdizszN MVTTRW5ITVJ?
LB1047-RCC MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHF[Y5CUUN3ME2wMlA2Ojl4IN88US=> NHjod2VUSU6JRWK=
NCI-H2030 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHPPVlvUUN3ME2wMlA2PDF2IN88US=> Mk\NV2FPT0WU
YH-13 NFTr[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zTWM2OD1yLkC1O|IzKM7:TR?= MkPWV2FPT0WU
5637 NIfoO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEW3OEDPxE1? MoTIV2FPT0WU
LOXIMVI NYn6PGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13QfWlEPTB;MD6wOVg4OiEQvF2= NITHSHFUSU6JRWK=
GT3TKB NHWxN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDNd3NKSzVyPUCuNFU6PDJizszN M4LhV3NCVkeHUh?=
TCCSUP NH\1b5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LYWWlEPTB;MD6wOVk3PCEQvF2= MnX1V2FPT0WU
EPLC-272H NHLmNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjSTWM2OD1yLkC2NlA2KM7:TR?= M4Lj[XNCVkeHUh?=
LU-99A NGHjUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKwVWdLUUN3ME2wMlA3OjN5IN88US=> NVfJellJW0GQR1XS
NCI-H1755 M2i4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOxb|ZKSzVyPUCuNFY{PDFizszN NIPQN4RUSU6JRWK=
KM12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXaTWM2OD1yLkC2N|Q5KM7:TR?= NIPYXFFUSU6JRWK=
SF295 M2PkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\OTWM2OD1yLkC2OFUzKM7:TR?= MmjMV2FPT0WU
MZ2-MEL MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwME[1OVMh|ryP M1fEeXNCVkeHUh?=
HEC-1 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwME[1PFgh|ryP M1XzOXNCVkeHUh?=
SW684 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmxTWM2OD1yLkC2OVkyKM7:TR?= MoDaV2FPT0WU
SF539 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzuTWM2OD1yLkC2OlgyKM7:TR?= NEXuWpNUSU6JRWK=
GMS-10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TIdWlEPTB;MD6wOlY6QSEQvF2= NYrLWY03W0GQR1XS
MV-4-11 NHTHSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e5TWlEPTB;MD6wOlgxOyEQvF2= MlHhV2FPT0WU
HT-29 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwME[5NVkh|ryP M1n3c3NCVkeHUh?=
23132-87 M{TkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXTTWM2OD1yLkC2PVUh|ryP NWXUXIdrW0GQR1XS
SW620 M1ftR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEewNlYh|ryP M4SwZnNCVkeHUh?=
HCC1806 M1\PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEexN|Eh|ryP NIPsWWxUSU6JRWK=
Hs-578-T Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3xSGRKSzVyPUCuNFczODhizszN M3[zUHNCVkeHUh?=
A2058 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILZN49KSzVyPUCuNFczOjhizszN MlTSV2FPT0WU
MEL-HO M{TOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:3NppnUUN3ME2wMlA4OjV3IN88US=> Mmr3V2FPT0WU
HCC2998 NUDpcnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX4VJVDUUN3ME2wMlA4OzR5IN88US=> NUfFc2QzW0GQR1XS
HuO9 NHL4W2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjITWM2OD1yLkC3OVg6KM7:TR?= NXXNc|BzW0GQR1XS
CAL-39 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPqbFhKSzVyPUCuNFc4PjZizszN NVfXSINrW0GQR1XS
M14 NFTrO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLVXFN[UUN3ME2wMlA4QTF|IN88US=> NYLob5BpW0GQR1XS
BFTC-909 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzRZZFNUUN3ME2wMlA4QTZ7IN88US=> M1;Cd3NCVkeHUh?=
TE-11 M{nseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXuTWM2OD1yLkC3PVk3KM7:TR?= MoTnV2FPT0WU
TGBC1TKB NGLaOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEiwOFMh|ryP NU\5Vpd{W0GQR1XS
L-363 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEiyNFYh|ryP NVTpUZZtW0GQR1XS
A431 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLHOXpKSzVyPUCuNFgzOSEQvF2= NVvLbGdpW0GQR1XS
MKN45 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjhUGtKSzVyPUCuNFgzOTlizszN MUPTRW5ITVJ?
HT-1080 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEi0N|kh|ryP NH7TS49USU6JRWK=
OVCAR-8 NI\ZOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEi2NlIh|ryP MUXTRW5ITVJ?
LCLC-97TM1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMEi3Nlgh|ryP NVXTfpkzW0GQR1XS
M059J NVrFOIRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4e4hHUUN3ME2wMlA6ODJ5IN88US=> Mn;xV2FPT0WU
SK-MEL-2 M2jYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj4TWM2OD1yLkC5NFYh|ryP MX3TRW5ITVJ?
TE-1 NWTmTJJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyxS5AyUUN3ME2wMlA6OjB2IN88US=> M2XjeHNCVkeHUh?=
KYSE-180 NH;uS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LLXGlEPTB;MD6wPVI3OiEQvF2= MYHTRW5ITVJ?
D-247MG NFrTNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\aTWM2OD1yLkC5OFU2KM7:TR?= MnjpV2FPT0WU
8-MG-BA NYO2UnFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[wTWM2OD1yLkC5OFczKM7:TR?= NG\t[2NUSU6JRWK=
NCI-H1792 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlznTWM2OD1yLkC5OlE5KM7:TR?= M2LN[HNCVkeHUh?=
MCF7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknLTWM2OD1yLkC5Olc4KM7:TR?= NVX3b3VTW0GQR1XS
NCI-H2122 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnGZ4RKSzVyPUCuNFk4PDVizszN MYTTRW5ITVJ?
EFO-27 NETzNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvyTWM2OD1yLkC5PVk4KM7:TR?= NXrwW5E5W0GQR1XS
LB2241-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq5XIdUUUN3ME2wMlExODV2IN88US=> M1\HZ3NCVkeHUh?=
SN12C MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SyNGlEPTB;MD6xNFExPyEQvF2= M3niTXNCVkeHUh?=
A498 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7SVJBVUUN3ME2wMlExOThizszN NEflbFNUSU6JRWK=
PANC-03-27 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjpTWM2OD1yLkGwNlg3KM7:TR?= NGC5c2FUSU6JRWK=
NCI-H1581 NYfpZWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LDSWlEPTB;MD6xNFI6KM7:TR?= NGHScFZUSU6JRWK=
U-87-MG NFfrV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTqTWM2OD1yLkGwN|A4KM7:TR?= MYTTRW5ITVJ?
G-401 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjWTWM2OD1yLkGwN|U{KM7:TR?= MXvTRW5ITVJ?
SiHa NHjL[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfXb4pKSzVyPUCuNVA1QDZizszN NYnBVGU3W0GQR1XS
U251 NVPv[|RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUC1NlUh|ryP NHflR21USU6JRWK=
MMAC-SF NXjzeplLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\CTWM2OD1yLkGwOVMyKM7:TR?= M{DaSnNCVkeHUh?=
BB65-RCC M1zPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLkV4IxUUN3ME2wMlExPTV2IN88US=> M172fXNCVkeHUh?=
NKM-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjuTnNKSzVyPUCuNVA3PjZizszN NIf0cpJUSU6JRWK=
HD-MY-Z M{nNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PreWlEPTB;MD6xNFg4OyEQvF2= MkHaV2FPT0WU
TGBC11TKB NGTlPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7KTWM2OD1yLkGwPVA{KM7:TR?= NXLyUlhYW0GQR1XS
COLO-679 NIG0NWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj6TWM2OD1yLkGxNlEyKM7:TR?= MlTEV2FPT0WU
TE-8 NE\2UJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\VPG5mUUN3ME2wMlEyOjZ2IN88US=> MmjXV2FPT0WU
SK-MEL-28 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITWZYxKSzVyPUCuNVE{OjFizszN NE\zN41USU6JRWK=
SH-4 NE\WSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH60WXFKSzVyPUCuNVE{PTZizszN NHP5eldUSU6JRWK=
KALS-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pq[WlEPTB;MD6xNVM6OyEQvF2= MU\TRW5ITVJ?
RKO M4PhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP1XZpyUUN3ME2wMlEyPzZ2IN88US=> M3z6enNCVkeHUh?=
OMC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Gd2lEPTB;MD6xNVc6PyEQvF2= NInoNo9USU6JRWK=
BT-549 M2L1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMUG3PVkh|ryP MnKwV2FPT0WU
NCI-H28 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7iTWM2OD1yLkGxPFE4KM7:TR?= NYXSNppxW0GQR1XS
RXF393 NHv1WIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzXTWM2OD1yLkGxPVgzKM7:TR?= MW\TRW5ITVJ?
COLO-829 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX5SllKSzVyPUCuNVIxODVizszN M17JRnNCVkeHUh?=
HMV-II M2TCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L5N2lEPTB;MD6xNlAzKM7:TR?= MWPTRW5ITVJ?
SW1990 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;vdnBYUUN3ME2wMlEzOTV5IN88US=> MofBV2FPT0WU
NCI-H1437 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrVW4dOUUN3ME2wMlEzOTV5IN88US=> NEL4Z5BUSU6JRWK=
SNB75 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW5fXpKSzVyPUCuNVIyPjlizszN MojPV2FPT0WU
EW-3 NYqwXIc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zTWM2OD1yLkGyOlYyKM7:TR?= MXzTRW5ITVJ?
SAS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMUK2PUDPxE1? MYPTRW5ITVJ?
NCI-H1666 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHLenZTUUN3ME2wMlEzPzd2IN88US=> M2DG[XNCVkeHUh?=
A375 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;BPXhKSzVyPUCuNVI4PzhizszN NGC0cI9USU6JRWK=
CAMA-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;1TWM2OD1yLkGyPVI1KM7:TR?= MYPTRW5ITVJ?
HuP-T4 M3rBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq1TWM2OD1yLkGyPVQ{KM7:TR?= Ml\ZV2FPT0WU
NCI-H292 NWDxb3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fuTWlEPTB;MD6xN|EyKM7:TR?= MkTPV2FPT0WU
PC-14 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPZTWM2OD1yLkGzNlEyKM7:TR?= M{D5SXNCVkeHUh?=
BPH-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj1PXhKSzVyPUCuNVM1OSEQvF2= NVLhVIFUW0GQR1XS
GAK M3W4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHjTolKSzVyPUCuNVM2PjdizszN Mn;RV2FPT0WU
VMRC-RCZ NHf2OZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCwTWM2OD1yLkGzO|YzKM7:TR?= M2\NVXNCVkeHUh?=
SK-MEL-24 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTQd3BKSzVyPUCuNVM5PyEQvF2= NUnUPJB5W0GQR1XS
LB831-BLC NInSOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfsNWpKSzVyPUCuNVM5QDNizszN M2PHWnNCVkeHUh?=
NCI-H2452 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLGTWM2OD1yLkGzPVU3KM7:TR?= MoPRV2FPT0WU
RT-112 NELCe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUSwN|Uh|ryP M1H1NXNCVkeHUh?=
GP5d M1LWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L4d2lEPTB;MD6xOFExPCEQvF2= MXrTRW5ITVJ?
LC-2-ad M4\zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7QW|JzUUN3ME2wMlE1OTJzIN88US=> MkG0V2FPT0WU
MPP-89 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHEWZZKSzVyPUCuNVQyOjVizszN NV;kbmZjW0GQR1XS
NUGC-3 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC0SpdKSzVyPUCuNVQ1PzhizszN NHnZSItUSU6JRWK=
GI-1 NXHN[nlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPXTWM2OD1yLkG0OVU5KM7:TR?= MWXTRW5ITVJ?
HCC1419 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfuTWM2OD1yLkG0OVc3KM7:TR?= MXXTRW5ITVJ?
SW1573 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMUS3OVgh|ryP MlHzV2FPT0WU
NCI-H2347 M1jndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXnTWM2OD1yLkG0PFM6KM7:TR?= NYrLSnBJW0GQR1XS
Mewo MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMUS4PFkh|ryP MYXTRW5ITVJ?
639-V MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUWwNVMh|ryP MVvTRW5ITVJ?
AsPC-1 NULsXndUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPRTWM2OD1yLkG1NlI2KM7:TR?= MknTV2FPT0WU
NCI-H1648 NIDoUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMUWyN|Ih|ryP NXXLOpF3W0GQR1XS
786-0 M3rz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\iPItKSzVyPUCuNVU{QDFizszN Mn;MV2FPT0WU
ETK-1 NGPuU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMUW5JO69VQ>? MUXTRW5ITVJ?
BxPC-3 NHzRVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm5eHFKSzVyPUCuNVU6PjZizszN NV\LeXNDW0GQR1XS
CAL-62 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;1TWM2OD1yLkG2NVY6KM7:TR?= M{HvUXNCVkeHUh?=
HCC1937 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3xTWM2OD1yLkG2Nlc2KM7:TR?= MkLZV2FPT0WU
NCI-H1299 NXzseIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjvTWM2OD1yLkG2Nlg2KM7:TR?= M1zucHNCVkeHUh?=
SW1088 NYTCdHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfJT3Q4UUN3ME2wMlE3PDF|IN88US=> MXrTRW5ITVJ?
FTC-133 NWqwW4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Lk[GlEPTB;MD6xOlU1KM7:TR?= Ml;DV2FPT0WU
OC-314 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OwNGlEPTB;MD6xOlY6KM7:TR?= MmDoV2FPT0WU
SCC-9 M4HoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT4TWM2OD1yLkG2O|E3KM7:TR?= NIK1VI5USU6JRWK=
HT-1376 NEW5WXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITMXnhKSzVyPUCuNVY6OzZizszN M176OXNCVkeHUh?=
U-2-OS NFLiNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXKVIN{UUN3ME2wMlE4OTd|IN88US=> NFW4PJBUSU6JRWK=
COLO-824 NFPQZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUeyPVQh|ryP NV3nemd1W0GQR1XS
BB30-HNC NV7LTYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXVNI4zUUN3ME2wMlE4OzNizszN MVHTRW5ITVJ?
NCI-H2087 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TremlEPTB;MD6xO|M3QCEQvF2= NILpVXFUSU6JRWK=
NCI-H2170 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITTRnhKSzVyPUCuNVc2OzZizszN NIfXSIZUSU6JRWK=
SK-OV-3 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzJSYZlUUN3ME2wMlE4PTdzIN88US=> MoS4V2FPT0WU
MZ7-mel NIHiRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nIOmlEPTB;MD6xO|Y1QSEQvF2= NHXLfmpUSU6JRWK=
NCI-H650 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDU[GRKSzVyPUCuNVc3QDJizszN M3rWVHNCVkeHUh?=
KOSC-2 MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLtTWM2OD1yLkG3O|M1KM7:TR?= M2GzOXNCVkeHUh?=
SCC-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMUe3O|ch|ryP MVTTRW5ITVJ?
MDA-MB-157 NIjyZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMUiwPFIh|ryP M3S0O3NCVkeHUh?=
KYSE-520 NUfCWYE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDPNpNKSzVyPUCuNVgzKM7:TR?= NETie3VUSU6JRWK=
LK-2 NV\JbIVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S1NGlEPTB;MD6xPFMxOyEQvF2= NV:xbXVFW0GQR1XS
KNS-81-FD MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMUizPVQh|ryP M4rac3NCVkeHUh?=
IGROV-1 NX7n[4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMUi0OFMh|ryP NYDOOIVOW0GQR1XS
DEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfjTWM2OD1yLkG4OFUh|ryP MVrTRW5ITVJ?
NCI-H1395 M{W0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfoUI9kUUN3ME2wMlE5Pjh{IN88US=> MkjQV2FPT0WU
JEG-3 NX3BPYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDkNIJKSzVyPUCuNVg4ODVizszN NVHpb4M2W0GQR1XS
BCPAP MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDuTWM2OD1yLkG4PFczKM7:TR?= NVrjV3Y6W0GQR1XS
CAL-27 MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXNdHdKSzVyPUCuNVkxOjJizszN NGTxZZRUSU6JRWK=
RD Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMUmxNVMh|ryP NEDnblRUSU6JRWK=
RVH-421 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMUmxNVYh|ryP M3ez[3NCVkeHUh?=
Capan-2 NWX2dXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUmyOVYh|ryP M4radXNCVkeHUh?=
COLO-680N NF\iVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMUmzOlQh|ryP M1PhbXNCVkeHUh?=
NCI-H1650 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrvR5VKSzVyPUCuNlAxPTdizszN NHfyZWFUSU6JRWK=
SBC-5 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLNTWM2OD1yLkKwNVE5KM7:TR?= NXTjcGg3W0GQR1XS
U031 MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HZRWlEPTB;MD6yNFU1PyEQvF2= MonXV2FPT0WU
S-117 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTiRoFWUUN3ME2wMlIxPTZ2IN88US=> NWDJZldIW0GQR1XS
DoTc2-4510 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjNdolJUUN3ME2wMlIxPzZ7IN88US=> MUHTRW5ITVJ?
AM-38 NWrOcYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;LTWM2OD1yLkKwPFQ5KM7:TR?= MWDTRW5ITVJ?
A172 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDqZpBKSzVyPUCuNlExOjJizszN NFfKVYxUSU6JRWK=
HPAF-II M4nUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMkGyOlQh|ryP NVXU[pJXW0GQR1XS
769-P NWq5NnpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTnTWM2OD1yLkKxNlgh|ryP MnLTV2FPT0WU
MFE-280 NH:yfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMkGyPVgh|ryP NUfFVYFGW0GQR1XS
TE-9 NF:0W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMkG3PFYh|ryP NGC5d|JUSU6JRWK=
C2BBe1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PiZmlEPTB;MD6yNlE6KM7:TR?= M13z[nNCVkeHUh?=
EoL-1-cell MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PnZmlEPTB;MD6yNlIxOyEQvF2= NGqybIdUSU6JRWK=
G-361 NV7ZcZpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nnRmlEPTB;MD6yNlY5OiEQvF2= NGq3O4hUSU6JRWK=
KYSE-270 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWwbXc5UUN3ME2wMlI{ODh2IN88US=> MWXTRW5ITVJ?
TK10 NVroe3l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq5cXFKSzVyPUCuNlMyOTdizszN NWm4bGhDW0GQR1XS
ML-2 NI\xcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPlV3JKSzVyPUCuNlMyOTlizszN M1PPcHNCVkeHUh?=
MHH-ES-1 NYn0TJBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHld3ZEUUN3ME2wMlI{PjhzIN88US=> MliyV2FPT0WU
BHY MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTwdZpNUUN3ME2wMlI{PjlzIN88US=> MXzTRW5ITVJ?
LS-513 NF\HXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXuTWM2OD1yLkKzPVYyKM7:TR?= MXnTRW5ITVJ?
COLO-678 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHQZZVKSzVyPUCuNlQxPDRizszN M3rqd3NCVkeHUh?=
NCI-H747 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPFOnhKSzVyPUCuNlQyPjlizszN Mn7TV2FPT0WU
K5 NGrnR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMkSzPEDPxE1? MXXTRW5ITVJ?
OS-RC-2 M{nmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMkS1NFkh|ryP Mm[0V2FPT0WU
KINGS-1 NFfwVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMkS1Nlkh|ryP NGD1b5dUSU6JRWK=
SCC-25 M4PCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMkS1OlMh|ryP MWPTRW5ITVJ?
CAPAN-1 NF7QNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLse|U3UUN3ME2wMlI1Pzh|IN88US=> MXHTRW5ITVJ?
ESS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C3RmlEPTB;MD6yOFgxPSEQvF2= MXrTRW5ITVJ?
TE-6 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL4XWdLUUN3ME2wMlI2PzVizszN Mo\jV2FPT0WU
LB2518-MEL M3\aNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDheHBKSzVyPUCuNlU4PzdizszN M2TpUHNCVkeHUh?=
COLO-800 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfKTWM2OD1yLkK1PFEzKM7:TR?= MUDTRW5ITVJ?
LU-134-A M{Htemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMk[xN|Yh|ryP MX;TRW5ITVJ?
NCI-H1155 NILiUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjmeodKSzVyPUCuNlYyPjJizszN M4fwdnNCVkeHUh?=
MFM-223 NGfHN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOwTWM2OD1yLkK2N|Y{KM7:TR?= MkLEV2FPT0WU
HTC-C3 NX\kfHpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrCZo5KSzVyPUCuNlY2ODZizszN MnHhV2FPT0WU
HCT-116 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzXPWxQUUN3ME2wMlI3PTl7IN88US=> NYTRVJM6W0GQR1XS
Ca-Ski NHv6fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K5OGlEPTB;MD6yOlY4QCEQvF2= MYXTRW5ITVJ?
SBC-1 M3\vbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnEc5hUUUN3ME2wMlI3PzR{IN88US=> MlvoV2FPT0WU
NB69 M{f5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDVTWM2OD1yLkK3NFg4KM7:TR?= M2Lae3NCVkeHUh?=
J82 NHG4XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDadHpKSzVyPUCuNlczPjVizszN MmLmV2FPT0WU
U-118-MG NELVR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLLSYsyUUN3ME2wMlI4PTd7IN88US=> M4HWenNCVkeHUh?=
NCI-H1355 NUGzeYNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PEOGlEPTB;MD6yPFA4PCEQvF2= M4[yb3NCVkeHUh?=
NCI-H1048 MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfqc|NKSzVyPUCuNlg6PTZizszN M3LFZnNCVkeHUh?=
SW954 M{DObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf2PXpKSzVyPUCuNlkzOjdizszN NYfx[XRxW0GQR1XS
NMC-G1 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDoNHY6UUN3ME2wMlI6Ojd5IN88US=> NGHrdY9USU6JRWK=
SW1710 NFmzXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrtZ2I2UUN3ME2wMlI6PDl2IN88US=> NV[yO5FoW0GQR1XS
KY821 M3HudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n1WmlEPTB;MD6yPVg4OiEQvF2= MXTTRW5ITVJ?
HCC38 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi4dZdKSzVyPUCuN|AxPzhizszN M1vCeHNCVkeHUh?=
NCI-SNU-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTuTWM2OD1yLkOwOVQh|ryP NYrhR2FvW0GQR1XS
ES8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXCTWtKSzVyPUCuN|A4QDRizszN NW[2V4RHW0GQR1XS
COLO-792 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm2VnBKSzVyPUCuN|EzPTFizszN NYjkTI04W0GQR1XS
BFTC-905 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX0WVlKSzVyPUCuN|E2OjFizszN MkPpV2FPT0WU
ChaGo-K-1 MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjBTWM2OD1yLkOxO|E2KM7:TR?= M1H2b3NCVkeHUh?=
Daoy M3jJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zGRWlEPTB;MD6zNVczOyEQvF2= MnrEV2FPT0WU
SJSA-1 NYf6Om9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj4W2xOUUN3ME2wMlMyQDR5IN88US=> Ml3wV2FPT0WU
KNS-62 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwM{KwPFgh|ryP NGfyb4ZUSU6JRWK=
CAKI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m4OWlEPTB;MD6zNlEyOSEQvF2= M3mxbXNCVkeHUh?=
UACC-62 M2TKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\4WoJkUUN3ME2wMlMzOjJ5IN88US=> NVqxPGVNW0GQR1XS
HuCCT1 M1XvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DRfmlEPTB;MD6zNlI5OyEQvF2= NVjzfpVjW0GQR1XS
CTB-1 NUi1SpJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHhTWM2OD1yLkOyO|U{KM7:TR?= NUjHZZdCW0GQR1XS
NTERA-S-cl-D1 NH\MNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnIO2ZtUUN3ME2wMlMzQDN4IN88US=> NHTJUVdUSU6JRWK=
T-24 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvJTWM2OD1yLkOzNVU6KM7:TR?= NEH4UlVUSU6JRWK=
KYSE-70 NIrmRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7CNGdEUUN3ME2wMlM{Ojh|IN88US=> MYfTRW5ITVJ?
SW626 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwM{O1N|Ih|ryP MX\TRW5ITVJ?
LB996-RCC NFHK[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\TW2lEPTB;MD6zN|YyQSEQvF2= MoLwV2FPT0WU
DMS-273 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfXV5NKSzVyPUCuN|M6OTZizszN MoPJV2FPT0WU
SW1783 M4K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvGTWM2OD1yLkOzPVk4KM7:TR?= NIfpdWNUSU6JRWK=
KU812 NETZU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwM{SwN|gh|ryP NWrNV451W0GQR1XS
HSC-2 M1ftcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknJTWM2OD1yLkO0NFU{KM7:TR?= MXTTRW5ITVJ?
A3-KAW M1TaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID4TJdKSzVyPUCuN|QyPjJizszN MmjFV2FPT0WU
COLO-684 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwM{S1NFEh|ryP MmHwV2FPT0WU
NCI-H2405 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwM{S2N|Eh|ryP NIDaZmZUSU6JRWK=
NCI-H2228 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsTWM2OD1yLkO1N|U4KM7:TR?= M3TpRXNCVkeHUh?=
NB13 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjZVYdvUUN3ME2wMlM3QDJ7IN88US=> MYPTRW5ITVJ?
no-11 NYixdYVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HNWGlEPTB;MD6zOlk2KM7:TR?= MUPTRW5ITVJ?
DK-MG Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwM{exPFgh|ryP NYn3RmN5W0GQR1XS
NBsusSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzaXYtzUUN3ME2wMlM4Ojh3IN88US=> MXrTRW5ITVJ?
KP-N-YS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33wfGlEPTB;MD6zO|Q3OyEQvF2= M3zRRnNCVkeHUh?=
CFPAC-1 NEHFVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfSTWM2OD1yLkO3OVE5KM7:TR?= MW\TRW5ITVJ?
KARPAS-45 NUTYSVZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rOdmlEPTB;MD6zO|g3OiEQvF2= NFuyTlRUSU6JRWK=
NCI-H1793 NGLHdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDsTWM2OD1yLkO4OVEh|ryP M3XzR3NCVkeHUh?=
HCE-T MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwM{i2NFMh|ryP Mn3LV2FPT0WU
NCI-H520 NETve5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwM{i3NFMh|ryP NF3lTXJUSU6JRWK=
HCC2157 NYP3SolIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrJTWFKSzVyPUCuN|g4QDFizszN MXzTRW5ITVJ?
EW-18 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGezS29KSzVyPUCuN|g6PDFizszN M{[2dXNCVkeHUh?=
RO82-W-1 NW\HXZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDvWYtiUUN3ME2wMlM6Pjl7IN88US=> MULTRW5ITVJ?
HuP-T3 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNECxOFMh|ryP MoLBV2FPT0WU
PANC-10-05 NEfPWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzKTWM2OD1yLkSxNVch|ryP M4XWN3NCVkeHUh?=
NCI-H1703 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXrVXM1UUN3ME2wMlQyPDR4IN88US=> MoLOV2FPT0WU
TE-10 M1rpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDyTWM2OD1yLkSxOFQ4KM7:TR?= M1;6bHNCVkeHUh?=
HOS NFzuNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwNEG2PFIh|ryP M4q1[HNCVkeHUh?=
LN-405 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWzd5NKSzVyPUCuOFE3QDdizszN Ml:xV2FPT0WU
A427 NW\FdFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTnc2x4UUN3ME2wMlQyQThzIN88US=> NIfLSINUSU6JRWK=
CAL-12T NGPCcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwNEK3PEDPxE1? MVzTRW5ITVJ?
SW756 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwNESxPFMh|ryP M4O0[nNCVkeHUh?=
YAPC Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;DTWM2OD1yLkS1NFgh|ryP NGHKbVhUSU6JRWK=
GOTO NIfiRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwNEWxOkDPxE1? NH;EXo5USU6JRWK=
C3A NEfwb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHJdmwxUUN3ME2wMlQ2PDN5IN88US=> NFfXdpFUSU6JRWK=
UM-UC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPt[W1KSzVyPUCuOFU1PyEQvF2= NIfH[WZUSU6JRWK=
NCI-H1573 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPVTWM2OD1yLkS1OVY6KM7:TR?= MoPUV2FPT0WU
LS-411N MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfXTWM2OD1yLkS2OVI4KM7:TR?= NXzTR2k5W0GQR1XS
COR-L23 NX\sNG5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr5UIJjUUN3ME2wMlQ3PzZ2IN88US=> M370enNCVkeHUh?=
HCE-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XwVmlEPTB;MD60O|Q1PiEQvF2= MYLTRW5ITVJ?
NCI-H2291 NWPhcVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwNEe4PVYh|ryP M3r0UnNCVkeHUh?=
A101D M3zFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoroTWM2OD1yLkS4NFU{KM7:TR?= M33RZXNCVkeHUh?=
HT-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInJW4FKSzVyPUCuOFgzOTdizszN M1ftVnNCVkeHUh?=
HOP-62 NXrC[ZU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[2TWM2OD1yLkS5PFY2KM7:TR?= MXjTRW5ITVJ?
PC-3 M1exN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ZdXZKSzVyPUCuOVE2ODdizszN NV20XIlzW0GQR1XS
CTV-1 NX;MT2J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwNUK2Olkh|ryP MnflV2FPT0WU
PANC-08-13 NHHYepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwNUOxO|ch|ryP NWHOdFVyW0GQR1XS
CAL-120 M4nt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vOUWlEPTB;MD61N|M6QSEQvF2= NIG5SmpUSU6JRWK=
UMC-11 NEnrNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfsenJCUUN3ME2wMlU2OjN2IN88US=> NH;SbVhUSU6JRWK=
MSTO-211H NHHrOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LwZ2lEPTB;MD61OVc3OiEQvF2= NUfTPJNWW0GQR1XS
NCI-H2126 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXGN4hKSzVyPUCuOVY5OTVizszN NYriR4FWW0GQR1XS
SNU-C2B MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwNUe5O|ch|ryP MULTRW5ITVJ?
DBTRG-05MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XOOmlEPTB;MD61PFA2OyEQvF2= NGHHTlFUSU6JRWK=
MKN1 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrPTWM2OD1yLkW4O|g{KM7:TR?= NEDMcm5USU6JRWK=
ES3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwNUmxNlQh|ryP NYHVTVVmW0GQR1XS
OVCAR-3 M2i2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwNUmzOFEh|ryP NFfIU3JUSU6JRWK=
ACHN MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNkC1Olkh|ryP NWTsXZNuW0GQR1XS
SW872 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3eyXmlEPTB;MD62NFc3OyEQvF2= MofUV2FPT0WU
CP66-MEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNkC5Olkh|ryP NIrOfYVUSU6JRWK=
NCI-H661 NV7sOnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O2[2lEPTB;MD62NVExPCEQvF2= MUfTRW5ITVJ?
UACC-893 M4e5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD1yLk[zOlgyKM7:TR?= NUXWZVlqW0GQR1XS
JVM-3 M4\VUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vuVWlEPTB;MD62N|gxPCEQvF2= MmHaV2FPT0WU
SF268 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2zb5JvUUN3ME2wMlY1OzR7IN88US=> NW\neGNoW0GQR1XS
OCI-AML2 NYXHU3l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorzTWM2OD1yLk[1N|k4KM7:TR?= MVLTRW5ITVJ?
RPMI-8226 NXPkSlZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljMTWM2OD1yLk[2N|I{KM7:TR?= M{H1SXNCVkeHUh?=
MKN28 NULBT|FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vUUmlEPTB;MD62OlYzPCEQvF2= NX;wVWt1W0GQR1XS
MDA-MB-453 M4PTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzJTWM2OD1yLk[3NVgh|ryP NVP4codOW0GQR1XS
BV-173 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmwZWRKSzVyPUCuOlg3PzlizszN M3HG[nNCVkeHUh?=
NCI-H358 NXXMeHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNki3NlYh|ryP NH\Nd|VUSU6JRWK=
NCI-H1651 NWf3[3ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\GTmxKSzVyPUCuO{DPxE1? NX[zXIZTW0GQR1XS
MDA-MB-415 NX70Z|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwN{C4Nlkh|ryP NY\Keo1WW0GQR1XS
8305C MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr4O|RKSzVyPUCuO|I1QThizszN NWLpXo9LW0GQR1XS
EFM-19 NIXOPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwN{O2O|Eh|ryP NXrzTWtjW0GQR1XS
RERF-LC-MS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vEe2lEPTB;MD63OFYyOyEQvF2= MmLVV2FPT0WU
A388 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj4TWM2OD1yLke2OFY4KM7:TR?= MmDZV2FPT0WU
GI-ME-N NH3zZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jO[2lEPTB;MD63O|I{PSEQvF2= NUexdGRyW0GQR1XS
IGR-1 NU\MUFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DNUGlEPTB;MD63PVA1OyEQvF2= NHrBeIhUSU6JRWK=
LNCaP-Clone-FGC NF;wcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvPTWM2OD1yLkiwNFA1KM7:TR?= M3XFNnNCVkeHUh?=
SK-MEL-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2joSWlEPTB;MD64NVUxQCEQvF2= M2D0XnNCVkeHUh?=
UACC-257 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLiVWRKSzVyPUCuPFIzOzFizszN M2G4c3NCVkeHUh?=
OE33 NGP1WG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K3VGlEPTB;MD64OVExOSEQvF2= MXzTRW5ITVJ?
QIMR-WIL NH;K[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwOEWxOFEh|ryP M4\CcHNCVkeHUh?=
NCI-H2009 NG\Odo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwOEWzNVEh|ryP M3naN3NCVkeHUh?=
NCI-H522 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XQOGlEPTB;MD64O|c5OyEQvF2= MWXTRW5ITVJ?
Saos-2 M2faNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHvOXlKSzVyPUCuPFc5PzFizszN MlfjV2FPT0WU
NB17 M3:xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7uOZY{UUN3ME2wMlg5ODJ3IN88US=> NUjxboIyW0GQR1XS
D-392MG Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHFTWM2OD1yLki5N|U3KM7:TR?= NXfHeWRyW0GQR1XS
SHP-77 NF7teIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LLPGlEPTB;MD65NFQ5PSEQvF2= MnHjV2FPT0WU
SK-MEL-30 NGn0eGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DudmlEPTB;MD65NVE5PSEQvF2= M2LpdXNCVkeHUh?=
GCIY NHj1bHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHvTWM2OD1yLkmxPFQ{KM7:TR?= MlTZV2FPT0WU
HCC70 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP1cGNKUUN3ME2wMlkzODV7IN88US=> MmDrV2FPT0WU
LU-65 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nDWmlEPTB;MD65NlU6OSEQvF2= M2LXO3NCVkeHUh?=
NCI-H1563 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\OUnZTUUN3ME2wMlk1QDZ3IN88US=> NYjpZXdtW0GQR1XS
KURAMOCHI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHTblNKSzVyPUCuPVUyQTJizszN MnPPV2FPT0WU
PA-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\I[XNZUUN3ME2wMlk2PDJ2IN88US=> NWLrfoJmW0GQR1XS
NOS-1 M2TmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlziTWM2OD1yLkm3OFg6KM7:TR?= M{XkNnNCVkeHUh?=
NCI-H69 M4HvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPjRWtKSzVyPUCuPVc3OzRizszN MXXTRW5ITVJ?
KYSE-450 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG3TWM2OD1yLkm4OlI3KM7:TR?= NHTJTpVUSU6JRWK=
8505C MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjUdpVKSzVyPUCuPVk6QDJizszN M{naUXNCVkeHUh?=
TGBC24TKB MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD1zLkCwNFg1KM7:TR?= NHvPToFUSU6JRWK=
PFSK-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{POdGlEPTB;MT6wNVQzQCEQvF2= MVnTRW5ITVJ?
EKVX MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ywTGlEPTB;MT6wN|EzOSEQvF2= MYDTRW5ITVJ?
RCM-1 NXOxeGxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMEW1NFch|ryP M2j5XXNCVkeHUh?=
SW900 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwMEe4N{DPxE1? Ml7JV2FPT0WU
D-542MG NE[yeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2[2lEPTB;MT6wO|g2PSEQvF2= MY\TRW5ITVJ?
SK-PN-DW MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XzSWlEPTB;MT6xNFA2PiEQvF2= MoKyV2FPT0WU
NCI-H727 NUPDW2tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\0ZXFKSzVyPUGuNVAyPTRizszN MlXSV2FPT0WU
SW837 M1zweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nFSGlEPTB;MT6xNFk2PCEQvF2= NWDoUHVbW0GQR1XS
BT-20 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO2[oxYUUN3ME2xMlEyOjB2IN88US=> NYjQV5dPW0GQR1XS
RH-18 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGwTWM2OD1zLkGzNVA{KM7:TR?= M1HWOHNCVkeHUh?=
TE-12 NFLpbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wNoRlUUN3ME2xMlE{OzN|IN88US=> NGTLfFdUSU6JRWK=
NB10 NFP4OlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwMUOzOFQh|ryP Mn\IV2FPT0WU
AU565 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD0TWM2OD1zLkG1PVc{KM7:TR?= MknEV2FPT0WU
OAW-42 M1HVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwMUizNFYh|ryP NVHlT5gyW0GQR1XS
DJM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH0U4dKSzVyPUGuNVk5QDFizszN NEW1OnRUSU6JRWK=
HH NWOweZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjLTWM2OD1zLkKzPFMyKM7:TR?= NGXnN4FUSU6JRWK=
LAMA-84 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXTNZlKSzVyPUGuNlc{QTRizszN NWfENWpHW0GQR1XS
KNS-42 M2HsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrmTWM2OD1zLkOwNlk3KM7:TR?= MmLlV2FPT0WU
NCI-H2052 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXruXGhnUUN3ME2xMlMxPTB5IN88US=> Mnq5V2FPT0WU
MLMA MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvYR5VXUUN3ME2xMlMzPDB5IN88US=> NGC5TZFUSU6JRWK=
NB12 M4DoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofMTWM2OD1zLkO1OlM3KM7:TR?= MoXnV2FPT0WU
NCI-H1838 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfKTWM2OD1zLkO2N|A3KM7:TR?= MoPnV2FPT0WU
NCI-H526 M4Xafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\SbWlEPTB;MT6zO|g2OyEQvF2= NH7lO3RUSU6JRWK=
LS-123 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jKemlEPTB;MT6zPVA6PCEQvF2= NFjaUI5USU6JRWK=
HDLM-2 NI[yVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m2NWlEPTB;MT6zPVI4OSEQvF2= MUfTRW5ITVJ?
MC-IXC NWH0emx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzmTWM2OD1zLkSyN|cyKM7:TR?= MoDDV2FPT0WU
HCT-15 MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7PZZJKSzVyPUGuOFMxPjhizszN MXjTRW5ITVJ?
NCI-H596 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC5TWM2OD1zLkS1NFYyKM7:TR?= NHvhSm9USU6JRWK=
ZR-75-30 M1O3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD1zLkS3NFgzKM7:TR?= NXrSbVY5W0GQR1XS
A704 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwNk[1OlMh|ryP NILNcpFUSU6JRWK=
OVCAR-4 NITjeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfBZZBIUUN3ME2xMlY6PjB5IN88US=> M4HUSHNCVkeHUh?=
SW1417 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwN{K4OFkh|ryP NH;jfpZUSU6JRWK=
CAS-1 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\0VodHUUN3ME2xMlc{QTN4IN88US=> M1jPR3NCVkeHUh?=
IST-SL1 NIiweXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\QOVEyUUN3ME2xMlc6PzV7IN88US=> NWDzbHBVW0GQR1XS
A253 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr6VnpKSzVyPUGuPFIzOzlizszN M3;0NXNCVkeHUh?=
EW-16 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwOEK4O|Uh|ryP NW\6cok2W0GQR1XS
SK-NEP-1 NEn6flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwOE[5PFgh|ryP MknDV2FPT0WU
NCI-H226 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwOEmzOVkh|ryP M1W3b3NCVkeHUh?=
HOP-92 NXXZ[lVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jTVGlEPTB;MT65OlA6QSEQvF2= NHrJ[WZUSU6JRWK=
NCI-H441 NGT4SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrGTWM2OD1{LkCyN|M4KM7:TR?= MVHTRW5ITVJ?
LU-139 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvYNGdVUUN3ME2yMlA{OTF2IN88US=> NEfTNnpUSU6JRWK=
SJRH30 M324T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH0TWM2OD1{LkC0NlU{KM7:TR?= NFPPUYpUSU6JRWK=
MG-63 NEHNR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPCTWM2OD1{LkG0NVEyKM7:TR?= NHfkT21USU6JRWK=
NH-12 NXy3N4pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XPOGlEPTB;Mj6xOVAxPiEQvF2= NH;ZepVUSU6JRWK=
NB7 NFjOd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e3NmlEPTB;Mj6xPVY4OyEQvF2= M3zTUnNCVkeHUh?=
LB771-HNC M2jJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPYPGdKSzVyPUKuNlA2QTVizszN NIrBWGVUSU6JRWK=
HCC1569 M3\aS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nOT2lEPTB;Mj6yOFU5OyEQvF2= MV\TRW5ITVJ?
D-283MED NH;UfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK4W4pKSzVyPUKuNlQ4QDJizszN NFfiRVNUSU6JRWK=
J-RT3-T3-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTxS4YyUUN3ME2yMlI2OzVzIN88US=> NGDi[2JUSU6JRWK=
ATN-1 M4HQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33YR2lEPTB;Mj6zN|A5OiEQvF2= M3HWRnNCVkeHUh?=
HCC1954 NULQNVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyxfHlKUUN3ME2yMlM1PDB6IN88US=> M2DzeHNCVkeHUh?=
SCC-15 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILVS2ZKSzVyPUKuN|k{OTJizszN MWrTRW5ITVJ?
COLO-668 MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrpTWM2OD1{LkSzNkDPxE1? MWPTRW5ITVJ?
LB373-MEL-D M1vYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwNUS2O|ch|ryP MWfTRW5ITVJ?
no-10 NHnyWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHZSoZCUUN3ME2yMlU1QTR5IN88US=> MmjzV2FPT0WU
HT-1197 M1rDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HqTWlEPTB;Mj62N|E5QCEQvF2= NILtRZRUSU6JRWK=
DU-145 NFXyXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwN{mxOlIh|ryP NYiw[mwxW0GQR1XS
SK-N-AS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwOES2PVIh|ryP MkXlV2FPT0WU
MOLT-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwOEWzNlIh|ryP NGGwNZhUSU6JRWK=
EW-22 NYe1RVFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET1eVdKSzVyPUKuPVI5PDFizszN NHH6b5JUSU6JRWK=
DB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu2UWhTUUN3ME2yMlk4PzV7IN88US=> NW\l[IhTW0GQR1XS
HL-60 NVW5XItkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwMESzO|Yh|ryP M1OxNnNCVkeHUh?=
SK-N-DZ MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorwTWM2OD1|LkC1NFc2KM7:TR?= NGHKUXZUSU6JRWK=
NY MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\2TWM2OD1|LkC4OVQzKM7:TR?= MX;TRW5ITVJ?
T47D MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXR[FhrUUN3ME2zMlExPTV6IN88US=> M1myR3NCVkeHUh?=
NCI-H2029 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO1TWM2OD1|LkKyOFc4KM7:TR?= M4j6d3NCVkeHUh?=
KARPAS-299 NInEUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDwOJlKSzVyPUOuNlYxOjdizszN MmTvV2FPT0WU
KM-H2 M{OyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW2NGptUUN3ME2zMlMxPjhizszN NUT2NJUxW0GQR1XS
CHP-134 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnyUWtKSzVyPUOuOFc{QSEQvF2= M3mwb3NCVkeHUh?=
22RV1 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPsfVhKSzVyPUOuOFkyPjhizszN M1r6eXNCVkeHUh?=
NB5 M1jSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSyepd7UUN3ME2zMlUxPjh7IN88US=> NInIb4NUSU6JRWK=
CW-2 NYHTeItzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXFSnBEUUN3ME2zMlU2OzF2IN88US=> NWroOpNxW0GQR1XS
EFO-21 NYP6XW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDnUXdKSzVyPUOuOVY6PCEQvF2= M4S2SnNCVkeHUh?=
HuH-7 NXezOJFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL2fIZKSzVyPUOuOVg1OTRizszN NEXncmVUSU6JRWK=
ALL-PO NHPYRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\VZopRUUN3ME2zMlYzOzN3IN88US=> NFn0TVBUSU6JRWK=
EM-2 NWi5bXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHPXGVMUUN3ME2zMlY6ODFzIN88US=> MoHiV2FPT0WU
KLE NW\1[pJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;KfZRKUUN3ME2zMlc{ODJ7IN88US=> NX;EVlNnW0GQR1XS
NEC8 NIq3R3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwOUG4NFgh|ryP M3Pl[3NCVkeHUh?=
KP-N-YN MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fOVGlEPTB;Mz65N|Q4PiEQvF2= NEDP[olUSU6JRWK=
SK-MEL-1 M3HGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61d2ZHUUN3ME20MlA{PTF6IN88US=> NFLkW49USU6JRWK=
CAL-54 M3fUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zIR2lEPTB;ND6wOVkyKM7:TR?= MoTEV2FPT0WU
MS-1 MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nvdGlEPTB;ND6xOlE2PSEQvF2= M1W4bXNCVkeHUh?=
NCI-H209 NULSZXhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfYc|BKSzVyPUSuNlk6QTlizszN M1nDVnNCVkeHUh?=
NOMO-1 NHu3eXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwM{KxN|Eh|ryP M1;PTHNCVkeHUh?=
RPMI-2650 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwM{[zNlch|ryP MkKyV2FPT0WU
NCI-H810 NUfFZmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj4S3dKSzVyPUSuN|k4OzZizszN MVPTRW5ITVJ?
Ca9-22 M{exbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjKS2RKSzVyPUSuOFU3QTFizszN MnLmV2FPT0WU
ES4 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3kNXhKSzVyPUSuOFcxQTVizszN NXTScm5uW0GQR1XS
ES6 NVHJOYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjZepM1UUN3ME20MlQ6PjV5IN88US=> NGHlOlBUSU6JRWK=
DMS-114 M1XIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LaUWlEPTB;ND61OFY6OSEQvF2= NX;uW2lVW0GQR1XS
ONS-76 NFnifoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i1emlEPTB;ND61O|k2KM7:TR?= NWHud25oW0GQR1XS
K-562 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX73Um9bUUN3ME20Mlc{QDF2IN88US=> MX;TRW5ITVJ?
MHH-NB-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrUTWM2OD12Lke1OFYyKM7:TR?= NIjrZ2ZUSU6JRWK=
Calu-3 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTRwN{i1OFgh|ryP M37ac3NCVkeHUh?=
HT55 M3nJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r0emlEPTB;ND64OFU1PSEQvF2= Mn\OV2FPT0WU
SK-N-FI M1fSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTRwOEWwNFkh|ryP MXLTRW5ITVJ?
ES1 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTRwOE[wOVch|ryP M3excXNCVkeHUh?=
SF126 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnKcGhDUUN3ME20Mlk{OTh2IN88US=> MWLTRW5ITVJ?
ES5 NEfab5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwMUK0Nlch|ryP NHHKUGhUSU6JRWK=
LoVo Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\4TWM2OD13LkG1PFcyKM7:TR?= M33PT3NCVkeHUh?=
SNU-387 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHQcmpyUUN3ME21MlMzOzN7IN88US=> M2rZRXNCVkeHUh?=
C8166 M4GxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHZTWM2OD13LkO2N|M6KM7:TR?= MXHTRW5ITVJ?
LS-1034 NYCxRWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17XdGlEPTB;NT60NlMxPyEQvF2= M161fnNCVkeHUh?=
GR-ST MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7XTWM2OD13LkWyNlAyKM7:TR?= NUPkVmUzW0GQR1XS
NCI-H1092 NV\U[otGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7RTWM2OD13LkeyPFQ{KM7:TR?= M2m1b3NCVkeHUh?=
647-V NVTp[W1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;NTWM2OD13Lke0O|A3KM7:TR?= NHjxeGRUSU6JRWK=
EW-13 M1TYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DxXWlEPTB;NT63OlYzPyEQvF2= NV;aOW5GW0GQR1XS
KGN M17adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPOVnlsUUN3ME22MlA6QTJzIN88US=> NWXXXHE3W0GQR1XS
D-423MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn6S|JKSzVyPU[uOFAzQDRizszN MVjTRW5ITVJ?
ECC10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\afoF6UUN3ME23MlExOTBzIN88US=> M2HjOHNCVkeHUh?=
TE-5 NWPFOHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr1UZMzUUN3ME23MlQyOjl6IN88US=> NVTwZlRPW0GQR1XS
P12-ICHIKAWA NGLVcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTdwNEW1NlMh|ryP MnOyV2FPT0WU
NCI-H82 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TKZWlEPTB;Nz60OVcxOSEQvF2= NYDKVIVvW0GQR1XS
NCI-H1993 Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT1fmlKSzVyPUeuPFMxPjNizszN M1uzPHNCVkeHUh?=
RH-1 NWHkR5hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnyWmFKSzVyPUeuPFUzPDRizszN MoH6V2FPT0WU
SW948 NYDtN2xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\qbGlEPTB;Nz65OlA1QSEQvF2= Mo\hV2FPT0WU
CAL-33 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:5TWM2OD15Lkm5PVM5KM7:TR?= MX;TRW5ITVJ?
U-266 NHLDcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;UOFRZUUN3ME24MlE2Pzd5IN88US=> MXXTRW5ITVJ?
CAL-72 M2fESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRThwMkCzNkDPxE1? NVrtPG56W0GQR1XS
SNU-423 NIXyRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LrNGlEPTB;OT6zOlY3PiEQvF2= NGT2TWFUSU6JRWK=
KG-1 M4OwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfVVY1XUUN3ME25MlU5PDV4IN88US=> MkftV2FPT0WU
HCC1395 NWK4W5Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mzUGlEPTB;OT65NlM2OiEQvF2= MYHTRW5ITVJ?
BE-13 NEi2XVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEiz[oNKSzVyPUGwMlg5QTJizszN NX7McopIW0GQR1XS
MKN7 NVjkXpJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFyLkm3OlUh|ryP NIrXR2tUSU6JRWK=
697 M1HkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr2RZNmUUN3ME2xNU4yPDd{IN88US=> M{niO3NCVkeHUh?=
LU-135 NU\SO3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3BOWpNUUN3ME2xNU4zOzB5IN88US=> MX;TRW5ITVJ?
ES7 NHPyUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPyTWM2OD1zMT6zN|E{KM7:TR?= NF;ydWpUSU6JRWK=
SK-HEP-1 NEjHd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFzLke2OFYh|ryP NXT6eFFwW0GQR1XS
BEN NWrDemZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFzLki1NUDPxE1? MWDTRW5ITVJ?
NCI-H1770 M3\MTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF{LkGyOkDPxE1? M4jiRXNCVkeHUh?=
SW13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnOPHlKSzVyPUGyMlE2PDFizszN NEnvflJUSU6JRWK=
MZ1-PC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTFWJNKSzVyPUGyMlU1PTJizszN MWfTRW5ITVJ?
Mo-T NHrVTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn0TWM2OD1zMj63OFIyKM7:TR?= MXLTRW5ITVJ?
HLE MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjTbZlZUUN3ME2xNk45OjF3IN88US=> NYPKXYw1W0GQR1XS
RCC10RGB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17YVWlEPTB;MUOuOlcyKM7:TR?= M3zienNCVkeHUh?=
COLO-320-HSR NX65VZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OxWWlEPTB;MUOuO|M5OSEQvF2= NIPTcIZUSU6JRWK=
BHT-101 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrKdYtWUUN3ME2xN{45OzR3IN88US=> M{fBSnNCVkeHUh?=
OCUB-M NWCy[IJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK3cGZxUUN3ME2xOE4yPjB{IN88US=> MkPvV2FPT0WU
MEG-01 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;2WpNKSzVyPUG0MlM4ODhizszN M1vPc3NCVkeHUh?=
RS4-11 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXUSmRKSzVyPUG0Mlc1OiEQvF2= M2LibXNCVkeHUh?=
MN-60 M4\vSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\5WGlEPTB;MUSuO|g6PCEQvF2= MknBV2FPT0WU
NCI-H1304 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XvVWlEPTB;MUWuNFQzPSEQvF2= MnW2V2FPT0WU
Ramos-2G6-4C10 M3WwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF3LkC1PFEh|ryP M{jJbHNCVkeHUh?=
NCI-H2342 NXG5NHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TISWlEPTB;MUWuNlA1PCEQvF2= MWHTRW5ITVJ?
LAN-6 NFGwZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPBV|ZKSzVyPUG1MlQ1OTRizszN MVTTRW5ITVJ?
JVM-2 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojPTWM2OD1zNT61O|Q5KM7:TR?= NVPNfolLW0GQR1XS
P30-OHK MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF4LkC2NVQh|ryP MljnV2FPT0WU
C-33-A NYPEeoxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnFO4JKSzVyPUG2MlYzOTRizszN MlvpV2FPT0WU
RPMI-8866 NYnncY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC5TWM2OD1zNj64OFk3KM7:TR?= MW\TRW5ITVJ?
NCI-H630 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HF[2lEPTB;MU[uPFU{PyEQvF2= NIHwUnZUSU6JRWK=
KYSE-140 NIPERnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF5LkKwNlgh|ryP MkHCV2FPT0WU
T84 NUKyc5pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF6Lki2PVUh|ryP MVzTRW5ITVJ?
KU-19-19 NGnsS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy2TG5KSzVyPUG4Mlk3ODhizszN MoPDV2FPT0WU
BALL-1 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTXTWM2OD1zOT6zN|k6KM7:TR?= NInBNmNUSU6JRWK=
Calu-6 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fGUWlEPTB;MUmuOFkzKM7:TR?= NX\UUXNYW0GQR1XS
EGI-1 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmxTphKSzVyPUG5MlU6QCEQvF2= NYHGU5NNW0GQR1XS
MFH-ino NFjLUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluyTWM2OD1zOT63OFU1KM7:TR?= NEH0PGpUSU6JRWK=
GB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnMWFl{UUN3ME2yNE4{PTN3IN88US=> NFvjb2ZUSU6JRWK=
NCI-H1693 NHiyNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjXTWM2OD1{MD62OVA2KM7:TR?= MX;TRW5ITVJ?
SW1116 NHSyR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[xW2lEPTB;MkCuPVM3OiEQvF2= MWTTRW5ITVJ?
H-EMC-SS M{fQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ{LkC0OUDPxE1? MkTHV2FPT0WU
D-502MG NYi0dXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjTTWM2OD1{Mj64NlYyKM7:TR?= MXjTRW5ITVJ?
IA-LM MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O0R2lEPTB;MkOuNlQ6OyEQvF2= M2q3bXNCVkeHUh?=
SW1463 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K2dWlEPTB;MkOuO|kh|ryP M37UU3NCVkeHUh?=
JAR Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7PPIFKSzVyPUK0MlMzQTNizszN MYfTRW5ITVJ?
HT NH;pOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OzWWlEPTB;MkSuOFc2OyEQvF2= MUXTRW5ITVJ?
LCLC-103H M4jEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ2Lki0OFkh|ryP MoDEV2FPT0WU
SNU-449 NIDtSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ2Lki3OFEh|ryP NHy4UWtUSU6JRWK=
KE-37 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ3LkC5Nlgh|ryP NIfUT3ZUSU6JRWK=
NCI-H1623 NGfMXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnDSFJYUUN3ME2yO{4yOzB|IN88US=> NYSxc2N2W0GQR1XS
MOLT-13 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnYSI1KSzVyPUK3MlM2OTZizszN NHfjVoZUSU6JRWK=
COLO-741 NX\OOXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HCTWlEPTB;M{GuN|M{OyEQvF2= MlfHV2FPT0WU
NB6 NIPrN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfjN3lwUUN3ME2zNk4zQDd4IN88US=> NH3xToZUSU6JRWK=
MOLT-16 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN|LkCwOVUh|ryP M1nmfXNCVkeHUh?=
IST-MES1 M3nafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD1|ND6wOVQyKM7:TR?= M4DDPHNCVkeHUh?=
A4-Fuk M3fmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkeyTWM2OD1|NT6wOlYh|ryP MW\TRW5ITVJ?
CAL-85-1 M1i2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jw[2lEPTB;M{WuNlgyPyEQvF2= MW\TRW5ITVJ?
CCRF-CEM NFfnN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHXfYJKSzVyPUO3MlE2OzZizszN NWjz[GZ[W0GQR1XS
HAL-01 NWnBRohnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL0TWM2OD1|OD60PFg6KM7:TR?= M4DGZnNCVkeHUh?=
HEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID1eHpKSzVyPUSzMlM1ODlizszN NIPIVVNUSU6JRWK=
EW-1 MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET3SldKSzVyPUSzMlQ4PjhizszN M3P2OXNCVkeHUh?=
MDA-MB-231 M3fGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3wNIw2UUN3ME20OU4yOTl7IN88US=> M4HhfXNCVkeHUh?=
ABC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnUNIFKSzVyPUS2Mlg2OzhizszN MnjrV2FPT0WU
NCI-H446 M3S4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR6LkWwOVgh|ryP NEfmOXNUSU6JRWK=
MHH-PREB-1 M4i2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnjN3UyUUN3ME20PU43ODB5IN88US=> MmHLV2FPT0WU
DOHH-2 NEfkNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR7Lk[2OVYh|ryP M{facHNCVkeHUh?=
GCT M2XvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR7Lk[5O|Yh|ryP MmH6V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water <1 mg/mL
In vivo 5%DMSO+corn oil 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy 17-AAG (Tanespimycin) | 17-AAG (Tanespimycin) supplier | purchase 17-AAG (Tanespimycin) | 17-AAG (Tanespimycin) cost | 17-AAG (Tanespimycin) manufacturer | order 17-AAG (Tanespimycin) | 17-AAG (Tanespimycin) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID